Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate cancer (CRPC), responses are variable and short-lived. There is an urgent need to understand the basis of resistance...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Evans, Michael J., Smith-Jones, Peter M., Wongvipat, John, Navarro, Vincent, Kim, Sae, Bander, Neil H., Larson, Steven M., Sawyers, Charles L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2011
Pynciau:
Biological Sciences
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111331/
https://ncbi.nlm.nih.gov/pubmed/21606347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1106383108
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg